The combined utilization of GNAS and KRAS mutations as tumor markers has allowed for improved preoperative detection of IPMN; mutation in one or both of these genes has been observed in up to 96% of IPMN cases [12], with high sensitivity and specificity for IPMNs of approximately 79% and 98%, respectively [14]. The gene discussed is GNAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.